Just to add, as I'm sure some of our lawyers here could tell you, a series or "thicket" of patents can be filed by Cytodyn around specifics of the drug formulation, manufacturing process, etc. All may not be granted or may not hold up if challenged in court, but they make it more difficult and more expensive for others to operate within the biosimilar space for Leronlimab. This can lead to further market exclusivity. Not saying this is being done, but that it is a likely avenue, and more ammo against those saying Leronlimab has limited patent exclusivity remaining.

example given, Humira has(had) close to 100 patents filed (and most granted) around its formulation/manufacturing process.